Clinical trials: AIDS Dementia Complex
Depression, HIV Infections
PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects
Background: Human immunodeficiency virus (HIV) infection is a serious disease with no cure. Some people with HIV have depression and other mood problems. They can have problems with thinking and memory.
- Conditions
- Depression, HIV Infections, HIV-Associated Cognitive Motor Complex
- Trial name
- NCT03581305
- Testing
- 18F-FDOPA, 11C-DASB
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Depression, Stress, Psychological
Rural Dementia Caregiver Project
Rural caregivers face challenges of geographic isolation and lower health care access and quality. Many rural dementia caregivers experience serious health consequences due to caregiving responsibilities that can limit their…
- Conditions
- Depression, Stress, Psychological, Self Efficacy, Loneliness
- Trial name
- NCT04428112
- Testing
- Building Better Caregivers Workshop, Attention Control
- Where
- United States
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex
Effect of Cenicriviroc on HIV Neurocognitive Impairment
The study hypothesis is that cenicriviroc will improve cognition in HIV infected individuals with cognitive impairment. The investigators will study the effect of cenicriviroc on cognition in 24 subjects over a 24 week period.
- Conditions
- AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus
- Trial name
- NCT02128828
- Testing
- cenicriviroc
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Hawaii
HIV Infections
Clinical Trial of CNS-targeted HAART (CIT2)
CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI).
- Trial name
- NCT00624195
- Testing
- FDA Approved Antiretroviral Therapy (see list below)
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
HIV Dementia, HIV-Associated Cognitive Motor Complex
Intranasal Insulin for the Treatment of HAND
Infection with HIV (the virus that causes AIDS) can lead to problems with brain function, such as memory, concentration, judgment, and the speed or control of hands and legs.
- Trial name
- NCT03081117
- Testing
- Insulin, intranasal
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Johns Hopkins University
HIV Dementia
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
HIV associated neurological disorders (HAND), are a major problem even in ART treated people. HAND results from chronic inflammation which is largely attributed to expansion and activation of monocytes.
- Trial name
- NCT01600170
- Testing
- Atorvastatin (generic Lipitor)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
HIV-associated Cognitive Impairment, HIV Infections
Minocycline for HIV+ Cognitive Impairment in Uganda
Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline, an antibiotic, in the treatment of Human immunodeficiency virus (HIV)-associated cognitive impairment in Uganda.
- Trial name
- NCT00855062
- Testing
- minocycline
- Where
- Uganda
- Volunteers
- 73 people
- Sponsor
- Johns Hopkins University
HIV Dementia
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Activated monocytes play a key role in the pathogenesis of HIV-associated neurocognitive disorders (HAND). Individuals with HAND have expanded populations of activated monocytes.
- Trial name
- NCT01263938
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
HIV Associated Cognitive Motor Complex
Effect of Galantamine on Inflammation and Cognition
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be…
- Trial name
- CHI (NCT03384784)
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania